Fosun International Ltd lowered its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 41.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 237,783 shares of the company’s stock after selling 171,263 shares during the quarter. Oxford Immunotec Global PLC accounts for approximately 0.5% of Fosun International Ltd’s investment portfolio, making the stock its 22nd largest position. Fosun International Ltd owned approximately 1.03% of Oxford Immunotec Global PLC worth $4,000,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in OXFD. Teachers Advisors LLC boosted its stake in Oxford Immunotec Global PLC by 19.6% during the fourth quarter. Teachers Advisors LLC now owns 39,932 shares of the company’s stock valued at $597,000 after buying an additional 6,550 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Oxford Immunotec Global PLC by 1.9% during the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after buying an additional 254 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Oxford Immunotec Global PLC during the first quarter valued at about $1,135,000. Wells Fargo & Company MN boosted its stake in Oxford Immunotec Global PLC by 129.2% during the first quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock valued at $1,021,000 after buying an additional 37,163 shares in the last quarter. Finally, Parkwood LLC bought a new position in Oxford Immunotec Global PLC during the first quarter valued at about $176,000. 79.13% of the stock is owned by institutional investors and hedge funds.

In related news, COO Peter Edwardson sold 9,739 shares of Oxford Immunotec Global PLC stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $16.14, for a total transaction of $157,187.46. Following the completion of the sale, the chief operating officer now directly owns 92,905 shares of the company’s stock, valued at $1,499,486.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the sale, the director now directly owns 18,000 shares of the company’s stock, valued at $284,760. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 125,110 shares of company stock valued at $2,059,827. 7.58% of the stock is owned by insiders.

Several research analysts recently weighed in on the company. Zacks Investment Research cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, August 30th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $26.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. ValuEngine raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cowen and Company decreased their price target on Oxford Immunotec Global PLC from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Thursday, August 17th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.25.

Oxford Immunotec Global PLC (NASDAQ OXFD) traded up 0.72% during trading on Friday, hitting $15.32. The company had a trading volume of 136,329 shares. Oxford Immunotec Global PLC has a 12-month low of $11.71 and a 12-month high of $19.51. The company’s market capitalization is $353.52 million. The firm has a 50-day moving average of $16.14 and a 200 day moving average of $15.48.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting analysts’ consensus estimates of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The business had revenue of $26.10 million during the quarter, compared to analysts’ expectations of $25.05 million. During the same period in the previous year, the firm earned ($0.29) earnings per share. The firm’s quarterly revenue was up 35.9% compared to the same quarter last year. On average, equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.63) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Fosun International Ltd Decreases Position in Oxford Immunotec Global PLC (OXFD)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/17/fosun-international-ltd-decreases-position-in-oxford-immunotec-global-plc-oxfd.html.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.